No abstract

B7-H3, also called CD276, is a  type I  transmembrane glycoprotein that is encoded on human chromosome 15. It was discovered back in 2001. The original study described it as a  positive co-stimulant, as it can stimulate T-cell response and IFN-γ production. However, recent researches have shown that B7-H3 is involved in T-cell inhibition. A B7-H3 receptor has not been yet identified, and this may explain the complex immunomodulatory activity of B7-H3, as it can have more than one binding partner with different functions. Expression of the B7-H3 protein has been found on activated immune cells such as T-cells, NK cells and antigen presenting cells. Interestingly, it is overexpressed in a wide range of tumor cells and is associated with disease progression and outcome. The soluble form of this protein is also of particular interest. Increased sB7-H3 levels in the plasma of bone tumor patients might be their important diagnostic criterion.

No abstract

The data of a comparative enzyme-linked immunosorbent assay of the content of the soluble form of the immunity checkpoint VISTA in the blood serum of 30 healthy donors (control group), 79 patients with primary malignant (osteosarcoma - 30, chondrosarcoma - 31, chordoma - 14) and 14 borderline (giant cell tumor) bone neoplasms are presented. In the general group of patients with malignant neoplasms of bones, the median sVISTA content in blood serum is statistically significant lower than in the control (p = 0.040). In patients with bone tumors and healthy donors over 18 years of age, there was a decrease with age in serum sVISTA levels. There were no significant differences in sVISTA concentration between patients with osteosarcoma, chondrosarcoma and healthy donors. Only in patients with chordoma were sVISTA levels statistically significant lower than in controls (p = 0.013). In the groups of patients with chondrosarcoma and osteosarcoma of the bone, there were no significant associations between the serum sVISTA content and the main clinical and morphological characteristics of the disease. In patients with osteosarcoma, no relationship was found between sVISTA levels and overall survival rates, while in patients with bone chondrosarcoma, there was a tendency towards a favorable prognosis with a high content of the marker in the blood serum.

The article is devoted to study health-related quality of life and attitude to disease in 120 patients with bone tumor: osteosarcoma (41 persons), giant cell tumor (31 persons), chondrosarcoma (30 persons) and metastatic bone lesion (18 persons).Comparative analysis of quality of life basic parameters, attitude to disease and indices interconnections in four clinical groups of patients was made. Psychological methods were as follows: «SF-36 Health StatusSurvey», Quality of Life Questionnary-Core 30 of European Organization for Research and Treatment Cancer with module Bone Metastases 22, "The type of relation to disease". The results revealed differences in quality of life parameters, attitude to disease types and differences of correlations between the diagnostics indices in patients with different bone tumor types.